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There are various subgroups of patients with metastatic prostate cancer: polymetastatic, oligometastatic, or oligo-recurrent
cancers whose progression follows different courses and for whom there are different treatment options. Knowledge of
tumor dissemination pathways and different genetic and epigenetic tumor profiles, as well as their evolution during
disease progression, along with new diagnostic and therapeutic advances has allowed us to address these situations
with local ablative treatments such as stereotactic body radiation therapy or stereotactic radiosurgery. These treatments
provide high rates of local control with low toxicity in metastatic spread for primary cancers including those of pulmonary,
digestive, and renal origin, while these types of treatments are still emerging for cancers of prostatic origin. There are
several retrospective studies showing the effectiveness of such treatments in prostate cancer metastases, which has led to
the emergence of prospective studies on the issue and even some phase II studies intended to prevent or delay systemic
treatments such as chemotherapy. Here we collect together and review these past experiences and the studies currently
underway. These types of radiotherapy treatments redefine how we approach extracranial metastatic disease and open
up new possibilities for combination therapy with new systemic treatment agents.
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Restaging stage IV cancer
Beginning with Halsted [1] in 1907 various theories for
tumor dissemination have been proposed. The first im-
portant theory involved the locoregional lymphatic path-
way and hypothesized that the disease could be cured if
diagnosed at an early stage and if aggressively surgically
managed. More than 70 years later, a second model be-
came popular in oncological practice: using the breast
cancer model (also used by Halsted), this model pro-
posed that cancer is a systemic disease that always me-
tastasizes and thus will already have done so early in the
disease course, meaning that local therapies are less im-
portant than the tumor microenvironment or systemic
therapies [2-4]. Later a third theory was proposed based
in the "Spectrum hypothesis" [5] according to which the
disease ranges between local and disseminated at the
time of diagnosis. However, none of these theories has* Correspondence: antoniojconde@gmail.com
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Progression describes the cause of cancer as the accu-
mulation of acquired somatic mutations and chromo-
somal rearrangements which gradually add up over a
long period of time, progressively converting normal epi-
thelium into neoplastic cells which later acquire a meta-
static phenotype [7]. According to the "seed and soil"
theory once cells acquire this phenotype they gain a lym-
phogenic and angiogenic capacity for intravasation, ad-
hesion, and an ability to cause micrometastases [8]
which can thrive in any organ [9]. Certain tumors are
not sufficiently robust in one or more of these steps, re-
ferred to as “tumor dormancy”, which prevents the can-
cer from otherwise progressing. The patient’s immune
system appears to play a key role in this dormancy [10]:
This system has the ability to kill tumor cells, but there
may be balance situations in which it cannot completely
eliminate the disease and thus the cancer remains dor-
mant until an immunoediting phenomenon occurs
which prevents these cells from being perceived asCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Moreno et al. Radiation Oncology 2014, 9:258 Page 2 of 14
http://www.ro-journal.com/content/9/1/258antigenic by the immune system, thereby allowing the
disease to develop [11].
However, phenomena such as tumor mutations, adap-
tations, and changes in their genetic and epigenetic pro-
files cannot be explained by the theory of progression
and so new tumor models are emerging. Based on data
uncovered by the human genome project, Stephens et al.
[12] proposed the “chromothripsis theory” whereby hun-
dreds of genomic adjustments occur in an isolated cell
event which would be unlikely to occur in an aggregated
and a random manner accumulating over time; In this
theory key mutations among these adjustments trigger
catastrophic molecular changes which cause cancer. This
phenomenon has been observed in at least 2-3% of all
tumor sub-types and there is evidence for its involve-
ment in more than 25% of bone tumors. According to
this theory near catastrophic chromosomal breakage
occurs followed by telomere failure or dysfunction caus-
ing the union of different non-homologous genes which
could lead to the loss of tumor suppressor genes and/or
the activation of oncogenes. Phenomena with different
patterns of DNA breakage and hypermutability have also
been described in the prostate cancer model [13] sug-
gesting that a limited number of metastases (oligome-
tastases [6]) may occur early on which later seed others
after they become genetically unstable.
If metastases arise from clonal expansion [14] clones
with selective advantages would give rise to them, there-
fore destroying these clones (for example with ablative
radiotherapy techniques) would decrease their metastatic
potential. Consequently it is very important to distinguish
between different oncological situations; oligometastases,
term introduced by Weischelbaum and Hellman, describes
a situation where a patient has distant disease in a limited
number of regions (less than five) and where the primary
lesion can be controlled [5]. Yazuro Niibe [15] described
the term oligo-recurrence where a patient presents one or
more distant metastases or recurrences in one or more or-
gans, and in addition to the primary tumor being under
control, these metastases or recurrences may be amenable
to local treatment, leaving the possibility that no future
disease additional to that already described would occur.
Niiebe, Onishi, Chang and other experts [16] published a
prognostic classification based on the location and num-
ber of metastases, histology, and the moment of their
presentation along the course of the disease. This classifi-
cation specifically focusses on lung cancer but other
histologies could be included.
Another important method of metastasis classification
is Rubin’s amended TNM staging system [17]. He sug-
gests modifying the "M" to represent solitary metastasis
(M1), oligometastases (M2), or multiple metastases (M3),
and adding an "S" (depending on the presence and levels
of any serological markers), an "H" (using a modifiedKarnofsky scale to determine the condition of the patient),
and finally an "A" or "B" based on whether the patient is
symptomatic or not. The first two factors are important
for deciding upon and individualizing treatments and the
latter two take the patient’s general overall condition,
which is a better predictor of outcome, into account rather
than age specifically.
Prostate cancer metastases
Patterns of prostate cancer dissemination
Bubendorf et al. [18], in a series of 19,316 autopsies, of
which 1,589 presented prostate cancer, metastases were
detected in 35%: 90% were bone metastases, followed by
lung (46%), liver (25%), pleura (21%), and adrenal metas-
tases (13%); 90% of the bone metastases involved the
spinal cord. In terms of the pathways or patterns for this
spread, there is an eminent pattern of local extension
which occurs through the capsule, seminal vesicles, and
bladder, although Apex tumors may have an increased
extracapsular extension capacity due to their small
capsule size. The Denonvilliers fascia creates a natural
barrier to the rectum so extension at this level is rare.
Another important pathway is the lymphatic system,
which is involved in 9 to 16% of cases, especially at the
level of obturator, presacral, internal, and common iliac
arteries, and sometimes even the extra-regional paraaor-
tic chains. Hematogenous dissemination can also occur
through the cava to the liver and lungs.
Venous retrograde invasion through the Batson plexus,
leading from the prostate to the periprostatic veins and
presacral veins, column, and subsequently to the lungs is
one of the main routes of dissemination in metastatic pa-
tients. Indeed, there is evidence which proves this mech-
anism, such as the inverse relationship between spinal and
pulmonary metastases. Spinal cord involvement most
often occurs in smaller tumors (4 to 6 cm), while lung in-
volvement is more likely in large tumors (6 to 8 cm), with
liver involvement usually restricted to the largest tumors
(8 cm or larger), suggesting that spinal metastases precede
lung and liver metastases. Further supporting this idea, a
gradual decline in lumbar spinal and cervical vertebrae in-
volvement (97% to 38%) [19,20].
Diagnosis of metastasis in prostate cancer
The role of PSA (prostatic specific antigen) should be
highlighted in prostate cancer: it is a highly predictive
marker for bone metastases, with a positive predictive
value of 74% when present at a concentration greater
than 100 ng/mL and a negative predictive value of 98%
when present at less than 10 ng/mL. Other serological
tests, such as models based on circulating tumor cells,
are still in development.
CT (computed tomography) plays an important role in
detecting bone (mainly blastic), lung, and liver metastases
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diagnosis of liver, and especially, spinal metastases. New
non-parametric techniques such as whole-body (WB)
MRI and diffusion-weighted imaging (DWI) studies have
proven useful for detecting lymph node, bone, and visceral
metastases [21-26].
Undoubtedly, modern techniques such as PET (posi-
tron emission tomography) and CT have the greatest
versatility in terms of metastasis detection. Different ra-
diolabels that are useful for prostate cancer diagnosis
and tracking are in development, including markers of
cell membrane proliferation (11C/18F-choline), fatty
acid synthesis (11C- acetate), amino-acid transport and
protein synthesis (11C- methionine), androgen receptor
expression (18F- FDHT), sodium fluoride labeled with
fluorine 18 (sodium fluoride F 18 [18F-NaF]) and osteo-
blast activity (18F-fluoride). In the case of the latter,
there is more reported experience with 11C-choline and
18F-fluorocholine [27]; the main difference between two
is their half-life, which is considerably longer for 18F-
fluorocholine compared to 11C-choline (20 min vs. 110
min respectively) [28]. In addition, recently studies stand
out showing the role of 18F-NaF PET/CT as a highly
sensitive modality in revealing sites of occult osseous
metastases in prostate cancer [29,30] , moreover growing
evidence suggests that provides also increased specifity
in the detection of bone metastases and that combined
with other tracers such as F-FDG could provide additional
information [31-33].
Since the discovery of PET/CT, many authors have
proposed the use of these techniques in the diagnosis
and staging of prostate cancer and for restaging local
and systemic relapse patients, albeit with mixed results.
In order to try to unify these varied criteria and conclu-
sions Umbehr et al. [34] published a meta-analysis in
collaboration with the European Urology Association
which included 44 studies with 2293 patients, 25 of
them were in a staging setting and 19 were in relapse
(restaging setting). In patients for whom PET-CT was
used for initial staging, a sensitivity of 84% and specifi-
city of 79% was reached; the results were better for
restaged patients where a sensitivity of 85% and specifi-
city of 41.4% was obtained. However, the authors as-
sumed some limitations, such as heterogeneity among
the variables included in the different studies, which
prevented them from stratifying the sample. They con-
cluded that although the use of PET-CT allows the
correct staging and restaging of patients with prostate
cancer who have received prior radical treatment, it
should not be considered as a gold standard test in all
patients. Correct patient selection is necessary in order
to avoid false negatives.
Thus, when using this method in staging, high-risk
patients with a Gleason score of 8–10 and elevated PSAlevels (20 ng/ml or more) are the groups most suitable
for radical treatment [35]. In contrast, the most import-
ant predictive variables for patients in the restaging
group correspond to low levels of PSA (1 ng/ml or
more), short cell doubling times (less than 3 months and
up to 6), and an initial staging higher than pT3b or pN1
[36,37]. Therefore, despite all these advances we still
lack an accurate, direct, and reproducible “gold stand-
ard” imaging technique to delineate metastasized pros-
tate cancer.
Selection criteria for ablative therapy in metastatic prostate
cancer
Current guidelines, such as those from the National
Comprehensive Cancer Network (NCCN) [38] do not
include the possibility of ablative treatment for meta-
static prostate cancer, relegating the role of radiotherapy
to that of a palliative treatment for symptomatic patients.
This is in contrast to other pathologies, for example, colo-
rectal and pulmonary tumors where radiotherapy already
has a clear role [39,40]. The origin of this indication is
based on the good results obtained in a series of liver and
lung metastasectomies, although this does not exclude the
possibility that there are some oligometastatic prostate
cancer patients who could also benefit from such local
treatments [41,42].
In 2004 the University of Rochester [43] studied which
patient subgroups are most likely to develop oligometas-
tases. Using retrospective data from 369 patients who
were treated with external radiotherapy for primary
prostate lesions, the course of 74 patients (20%) who
developed metastases was studied: A follow-up over 10
years later determined that there was a significant in-
crease in overall survival (OS) in bone metastasis cases
(58% at 5 years and 27% at 10 years). They also noted
that pelvic bone metastases were associated with re-
duced survival when compared to spinal metastases. In
fact, patients with less than five metastases had better
survival compared to those with more than five metas-
tases (73% and 36% vs. 45% and 18% at 5 and 10 years
respectively). The metastasis-free interval after the pros-
tate cancer diagnosis was higher in those with less than
five lesions compared to those with more. It was also
found that survival from the time of the diagnosis of
bone metastases to death was not statistically significant
between these groups. Thus it was concluded that early
detection and aggressive treatment with surgery or radi-
ation is the best course of action.
Piet Ost et al. [44] tried to identify what prognostic
factors influence prostate cancer-specific survival (PCSS)
in non-castrated patients with metastatic prostate can-
cer, retrospectively analyzing 80 such patients. Univariate
analysis of the time interval from diagnosis to metasta-
sis, the pre-metastatic PSA duplication time (PSA-DT),
Moreno et al. Radiation Oncology 2014, 9:258 Page 4 of 14
http://www.ro-journal.com/content/9/1/258the number of metastatic lesions, pattern of metastatic
spread (especially lymph node and bone involvement),
and the treatment received at the time of metastases de-
tection were significant predictors for PCSS. However,
only pre-metastatic PSA-DT, the pattern of metastatic
spread, and the number of metastases were significant
predictors in the multivariate analysis. The number of
metastases found retained their ability to predict PCSS
even to a cutoff of one lesion, but when the cutoff was
between three and five they were not a significant pre-
dictor in multivariate analysis. Trying to identify a poor-
prognosis subgroup, they stratified patients according to
the number of metastasis (less than one metastasis to
more than one), and PSA-DT (three months or less to
more than three). All patients with one metastasis and a
PSA-DT of more than three months were alive at five
years compared to only 8% of patients more than three
and a PSA-DT of less than three months. The authors
concluded that a subgroup of patients with a longer
PSA-DT, node or axial skeleton involvement, and a
lower number of metastases have a better PCSS in non
castrate patients developing metastases.
According to present knowledge, the criteria for per-
forming ablative treatment in metastatic patients, and
particularly metastatic prostate cancer, patients would
be: oligo-recurrent patients (with a controlled or con-
trollable primary lesion) with five or fewer metastases
(ideally 1–3) located in the bone (preferably the spine, or
ganglions [45]) and take the patient’s overall condition
(e.g. age/Karnofsky score etc.) into account. Oligo-
recurrences in other metastatic locations such as in
the lung or liver (i.e. without bone or lymphatic in-
volvement) are currently anecdotal in the literature.
Treatment of bone and lymph node oligo-recurrence in
prostate cancer: lessons from palliative treatments and
surgery
Surgical experience of prostate cancer bone metastases
mainly focusses on spinal metastases, usually as a palliative
treatment. Different grading systems or "scores" have been
proposed to establish the indication and to select patients
suitable for spinal surgery. The first relevant system was
published by Tomita [46] and used prognostic factors such
as tumor growth/histology, the presence or absence of
visceral metastases, and the number of bone metastases to
indicate different surgical techniques. These "scores" were
evolved and completed by Tokuhashi [47] by taking the
patient’s Karnofsky index, the number of vertebral seg-
ments affected, and the presence or absence of motor or
clinical symptoms into account and is especially reliable
for certain prostate and breast metastasis subgroups [48].
Many factors must be considered when selecting dif-
ferent treatments for palliative-care patients including
the presence or absence of spinal cord compressionsyndrome, spinal stability, and histology [49,50]. How-
ever, the results from several reports (the majority retro-
spective) are contradictory and do not show a clear
advantage for any particular prognostic sub-group, only
a limited benefit of surgery in patients older than 70
years with a radioresistant histology [51-53] . In order to
protocolize management and individualize treatment,
different algorithms have emerged, for example NOMS,
used at the Memorial Sloan Kettering Cancer Center in
New York [54]. This system indicates different types of
treatment, depending on the patient's clinical neurological
and oncological situation, the degree of mechanical spinal
instability, and the status of their systemic disease.
Following on from the good results from the phase II
Radiation Therapy Oncology Group (RTOG) 0631 trial
which assessed the feasibility and safety of spinal SRS,
the phase III trial may obtain level 1 evidence for this
type of treatment [55] by comparing spinal SRS at a
single doses of 16 Gy to conventional treatment at a sin-
gle dose of 8 Gy in patients with 1–3 spinal metastases.
Taken together, these experiences, which are mostly
based on palliative-care patients, provide strong evidence
that experts should recommend SBRT or SRS rather
than conventional external beam radiation in oligometa-
static cases [56]. In fact, some RPAs (recursive partition-
ing analysis indexes) [57] have already been published
for spinal radiosurgery.
There are more than 133 clinical trials exploring the
role of ablative radiotherapy in different locations, 53 of
them in oligometastases and almost 18 in spinal metas-
tases. Focusing on prostate cancer treatment (discussed
in greater detail in sections below) current experience
suggests that single high doses may be preferable to
SBRT or SRS. For example, Muacevic et al. analyzed 40
patients with prostate cancer bone metastases (both
spinal and non-spinal); 75% of them were in a single
location, and the mean tumor volume was 13 cc. Fifty-
four consecutive radiosurgery sessions were adminis-
tered, with an average single dose of 20.2 Gy and after a
mean follow up of 14 months the actuarial local control
was 95.5% [58].
In terms of surgical salvage of prostate cancer lymph
node metastases, current experience is much more lim-
ited compared to other histologies. Randomized studies
like that of Verhagen et al. show that combined local
surgical treatment and hormone therapy is beneficial in
aggressive prostate cancer patients with nodal disease,
compared with hormone-only therapy [59]. Recent evi-
dence, as reflected by Haffner et al., shows that lymph
node metastases resected during radical prostatectomy
did not harbor PTEN, SPOP, TP53, or ATRX mutations,
suggesting that these lesions had an independent clonal/
sub-clonal origin [60]. No clear surgical benefit was
shown, and there was biochemical control in 9-19% of
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that in order to optimize treatments there must be
accurate patient pre-selection [61-63]; indeed, studies
using this strategy, such as that of Karnes et al., reach up
to 48% five-year progression-free survival (PFS) [64],
which has led to efforts to create new algorithms that
can select patient subgroups that are most likely to
benefit from rescue surgery [65].
Ablative radiotherapy studies of lymph node metastases,
both for prostate cancer and other histologies, are still
emerging. The work of Bignardi et al., among others, which
used SBRT to treat lymph node metastases with various
histologies, has shown this treatment to be a safe and ef-
fective option and have laid the groundwork for the future
study of prostate cancer lymph node metastasis [66-68].
Difficulties of ablative oligometastases treatment with
radiotherapy
Historically there have been a number of difficulties in
treating metastases with ablative radiotherapy doses: one
is the dose-limit tolerance of healthy tissue to fraction-
ation, a problem that was already successfully solved in
the development of cranial radiosurgery [69]. The asso-
ciation of high precision systems for determining the
position of the treatment volume using a stereotactic
frame, and the subsequent implementation of CT, MRI,
and other imaging techniques such as PET/CT allows
pinpoint accuracy and ensures adequate dose deposition.
The concept of hypofractionation has also been added,
which allows for extrapolation at an extracranial level, as
well as other modern techniques such as image-guided
radiation therapy; together these types of ablative treat-
ments are becoming generalized and now form part of
the treatments used in a large number of radiation on-
cology services.
Another difficulty is identification of patients that truly
fit the criteria for oligometastatic disease rather than, for
example polymetastatic or oligo-recurrent disease. In spite
of this, the development of new imaging techniques such
as WB-MRI and the introduction of new PET radiotracers
with enhanced diffusability (especially choline) has greatly
improved our ability to adequately select patients.
However, the greatest difficulty, and one that is inher-
ent to all ablative treatments, is that different cohorts of
oligometastatic sub-types must be taken into account. A
patient who is oligometastatic on diagnosis is not the
same as one who is oligometastatic after cytoreductive
(oligoprogressive) curative locoregional treatment, as they
would probably have different prognoses which would
require different therapeutic approaches. Therefore it is
essential to define the true oligometastatic stage, and as
such various theories have been proposed.
Oligometastasis is generally thought of as a situation
in which there is a long interval between primary diseasetreatment and the occurrence of a metastasis, which
would have a high percentage growth rate compared to
the primary tumor. Indeed, as Withers and Lee [70]
state, the greater the doubling time between excision of
the primary lesion and clinical detection of a "leader"
metastasis in relapsed patients is, the higher the likeli-
hood that the patient has an oligometastatic distribution.
Recently, Lussier et al. [71], studied different samples of
resected lung metastases in patients with limited meta-
static disease, and classified them according to the pa-
tient’s rate of disease progression, identifying different
microRNA expression patterns in patients with low or
high metastatic progression rates. The ability of these
phenotypes to predict survival progression was validated,
and they showed that microRNAs were able to predict
phenotypes in both data sets, differentiating between
those who eventually became oligometastatic and those
who developed polymetastatic disease. These results sup-
port the hypothesis that the presence or development of
oligometastases is a clinical entity with distinct biological
mechanisms that may differ from those in polymetastatic
disease [72].
Thus we can formulate the following hypothesis: patient
subgroups with a true oligometastatic disease phenotype
can benefit from high-dose ablative therapy which could
change their prognosis, and therefore they can receive
treatment beyond merely palliative care.
Fundamentals of bone, spinal and nodal stereotactic
body radiation therapy
The foundations of these new techniques can be defined
based on three principles: high-dose, high-precision, and
high conformation of the dose distribution to the target
volume.
High radiation doses per fraction: stereotactic ablative
radiotherapy
Several reports, such as those by Greco et al. [73] have
demonstrated that a high level of local metastasis con-
trol (around 90%) can be obtained regardless of the
patient’s histology when single fractions over 21 Gy or
fractionated doses over 8 Gy are administered. This type
of response is due to the radiobiological effect of high
doses [74]; while tumor stem cells are the target in
conventional radiotherapy, a dose per fraction above 8
Gy causes damage to tumor vessel endothelia, causing
intracellular release of ceramides which can also damage
to tumor stroma. The same mechanism has been linked
to the systemic immunomodulatory effect of these treat-
ments, [75] also defined as the abscopal effect.
Cell apoptosis can be initiated by DNA damage induced
by stereotactic ablative radiotherapy (SABR) which causes
positive p53 tumor suppressor gene regulation, and may
also trigger lipid cell membrane damage. This damage is
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tivate the stress-activated protein kinase/c-Jun N-terminal
kinase (SAPK/JNK) signaling pathway which in turn can
upregulate protein kinase R (PKR) expression, potentially
inducing major histocompatibility complex (MHC) and
cytokine expression via NF-kB, resulting in cellular expres-
sion of MHC class I, adhesion molecules, co-stimulatory
molecules, heat shock proteins, inflammatory mediators,
immunomodulatory cytokines, and cell death receptors
[76]. This type of effect is being explored with immunother-
apy in histologies such as melanoma, and more recently, in
prostate cancer [77].
High conformal radiotherapy
Precise conformation treatment is required in the use
of SABR because there is a high dose gradient between
the target volume and the dose-limiting organs at
risk. Ablative radiotherapy techniques require precise
treatment conformation to maintain correct patient
immobilization, accomplished by using one of several
commercial immobilization systems which promote
patient stability and comfort. It is also very important
that these systems are compatible with MRI and PET/
CT, given that they may be used for fusion imaging
with the radiotherapy planning CT to generate the
treatment position. Thus, most radiotherapy planning
systems allow either rigid or deformable registration
image fusion with other studies. There are currently
two trends for ablative vertebral treatments: the use
either of fusion imaging with MRI to delineate the
spinal cord or a myelogram during the planning CT
[78]. In contrast, most studies use choline-PET/CT for
nodal metastases.
Another key aspect of conformational high-dose
radiotherapy is the development of intensity modu-
lated radiotherapy (IMRT), and more recently, volu-
metric radiotherapy or arc radiotherapy (VMAT and
Rapid Arc) [79] which allow high conformation of the
treatment. For the theoretical conformation plotted
by the treatment planning system to be successfully
translated into a real patient treatment, it must remain
stable during the administration and, more import-
antly, we must ensure that the dose is deposited in the
correct place, leading us to the third principle: high
precision.
High precision
The fundamental tool used to give high precision in
radiotherapy treatments is the use of image guided radi-
ation therapy (IGRT) [80] which determines the position
of the patient, the target volume, and the organs at risk
at the time of treatment administration. There are sev-
eral devices on the market (cone beam tomography with
kilovoltage, megavoltage, stereoscopic images, infraredsensors, laser surface scanning systems, or by implant-
able radiofrequency position sensors), which can all be
combined and integrated in different ways in different
commercial solutions Figure 1.Current experience in radiotherapy treatment of prostate
cancer oligometastases
There are several documented experiences that focus on
radiation treatment of prostate cancer oligometastases
and although most of them focus on general oligometas-
tasis treatment or on spinal or nodal metastases, some
prostatic-origin cases are included because it is a com-
mon presentation [81].
Using 3D dynamic IMRT techniques, Schick et al. [82]
published data on 22 oligometastatic prostate cancer pa-
tients; 55% of them presented only one lesion and re-
ceived combined treatment with hormones and doses up
to 65 Gy with conventional fractionation. 18F-choline or
11C-acetate PET-CT were used to diagnose and delin-
eate the lesions, and identified 9 cases of local nodal
relapse, 6 of distal nodal relapse, 6 bone metastases, and
1 visceral metastasis. With a median follow-up of 39
months (range 11–75 months), biochemical relapse-free
survival (BRFS) at 3 years was 63% and OS was 89%.
Multivariate analysis established that BRFS is a variable
associated with an age over 61 years.
Another study using IMRT techniques and conventional
fractionation, Würschmidt et al. [83] analyzed 26 patients,
7 of them primary tumors, and 19 recurrences. They re-
ceived a median dose of 75.6 Gy to the primary tumor and
66.6 Gy to lymph node sites. OS at 28 months was 94%
and BRFS was 83% for the primary tumor and 49% for re-
currences and 100% for distant disease-free survival in the
primary tumor and 75% in recurrences.
Focusing on ablative radiotherapy schedules in patients
with a local relapse, Casamassina et al. [84] analyzed data
from 71 patients who had had different primary treat-
ments (post-prostatectomy, post-radiotherapy, or both),
all of whom were treated using SBRT techniques. Thirteen
patients presented persistent disease regression, two had
bone metastases, and 8 had lymph node recurrences (all
of them outside the irradiated areas). PSA fell from 5.65
ng/ml to a median 1.40 ng/ml in complete regression pa-
tients, and the nadir value (median 1.06 ng/ml) was main-
tained for a median of 5.6 months. Using a Cyberknife®
Jereczek-Fossa et al. [85,86] reported data from 38 lesions
in 34 patients; 15 of them were re-irradiated after local
relapse, four after an anastomosis relapse, 16 after nodal
relapse, and 3 were treated for a single metastasis (two
retroperitoneal and one bone). PET/CT with 11C-choline
was used for diagnosis in 30 cases and a 33 Gy 3-fraction
or 36 Gy 3-fraction dose scheme was used to treat lymph
node or bone metastases respectively.
Figure 1 Case report: Patient treated with SBRT and evaluation of response to the changing pattern of ADC in MRI. Patient diagnosed
of 3 bone metastasesof prostate cancer by PET/CT Fluror-Choline and diffusion MRI treated with SBRT (3 fractions of 10 Gy). Assessment by MRI
diffusion technique, suggestiveof response to treatment.
Moreno et al. Radiation Oncology 2014, 9:258 Page 7 of 14
http://www.ro-journal.com/content/9/1/258Median follow-up was 16.9 months. Acute urinary tox-
icity was described in 8 patients (in three cases grade 1
and in five cases grade 2) and rectal toxicity presented
only in one case (grade 1). Late-onset urinary toxicity
occurred in five cases (in three cases grade 3 and in two
cases grade 2) and one case each of grade 1 and grade 2
late-onset rectal toxicity was described. A biochemical
response was observed in 32 of 38 evaluable lesions,
PSA stabilization was observed in four lesions, and in
two cases PSA progression was reported. PFS was 42.6%
at 30 months and there was disease progression in 14 le-
sions (5, 2, 5, and 2 cases in the prostate, anastomosis,
lymph node, and metastasis groups respectively); pro-
gression was observed in only three cases. At the time of
analysis, 19 patients were alive without evidence of dis-
ease and 15 were alive with disease. In the case of nodal
metastases, at a median follow-up of 21.9 months 16
cases presented solely nodal relapse, 10 had a complete
response, there was one case of stable disease, and five
cases of disease progression, as assessed by choline-PET/
CT. At the level of PSA response, 12 complete re-
sponses, one partial response, two cases of stable disease,
and one case of disease progression were reported. With
regard to the three metastases, at a median follow-up of13.7 months, there was one case of radiological progres-
sion outside the treatment field, one case of disease
progression due to a rise in PSA, and one complete
response. The median PFS time was 11 months (range:
6–16 m) and no cases of toxicity were reported.
Using single doses of SRS with a Cyberknife® Muacevic
et al.[59] published data from a series of 40 patients; of
these, 19 received hormone therapy, and 64 bone metas-
tases were detected using 18F-choline PET/CT which
were treated with a mean single dose of 20.2 Gy (range:
16.6-22 Gy). Seventy-five percent of patients had only
one bone metastasis and 25% had two. Only 8 patients
received chemotherapy prior to ablative radiotherapy. At
a median follow-up of 14 months (range: 3–48 m) 95.5%
local control was described, as assessed by MRI and
PET/CT. Prior to SRS the median PSA was 5.4 ng/dl
which decreased to 2.7 ng/dl at three months. One
patient developed progressive neurological deficits after
treatment.
With respect to the management of oligometastatic
patients using ablative radiotherapy to delay the onset of
hormone therapy, Berkovic et al. [87] published their ex-
perience in the treatment of 24 patients with a biochem-
ical relapse, after initial treatment for three or fewer
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received hormone therapy. These patients were treated
with a schedule of 50 Gy in 10 fractions. Where bio-
chemical control was not achieved or new metastases
were detected (total fewer than three) during monitor-
ing, radiation therapy was re-administered. The authors
report 100% two-year local control, and 42% PFS at 2
years. Patients started hormone therapy if PSA levels
were greater than 50 or if the number of metastases
was greater than three; ten patients ultimately received
this treatment and had a median androgen deprivation
therapy-free survival of 38 months. No cases of grade 3




Type of lesions Treat
Casamassine
et al [84].
2011 71 patients: No A
- 28 post-prostatectomy
- 15 post-radiotherapy









2011 26 patients Mean
and 6
Ahmed et al. [89]. 2013 17 patients (21 lesions) Mean
Berkovic
et al. [87].
2012 24 patients with biochemical





2012 34 re-irradiated patients: 15 local





(2 retroperitoneal, 1 bone)





2014 83 patients biochemical recurrence
after radical primary treatment
No Athat treatment with ablative therapy can delay the use of
systemic therapies and has led to a phase II trial headed
by Dr. Piet Ost at the Ghent University Hospital (currently
recruiting) comparing surveillance versus SBRT treatment
or surgery in patients with prostate cancer oligometas-
tases, with the measure of androgen deprivation-free sur-
vival as primary endpoint [88].
Recently, Picchio et al. [45] published the results from
83 patients with lymph node relapses after radical pri-
mary treatment with simultaneous integrated boost (SIB)
therapy combined with Tomotherapy. Sixty-six patients
experienced a complete biochemical response, 12 a partial
biochemical response, 15 had disease progression, and oneradical radiotherapy in the management of
ment received Results
DT - 13 persistent regression
- 2 bone metastases
- 8 lymph node recurrences
(outside the irradiated áreas)
DT 95% local control
n dose 20,2 Gy (range 16,6-22 Gy)
tients chemotherapy
dose 75,6 Gy (primary site)
6,6 Gy (lymph node sites)
- Overall survival at 28 m: 94%
- Biochemical relapse free survival
(primary site): 83%; 49% (recurrences)
- Distant free survival 100% (primary site)
and 75% (recurrent)
dose 20 Gy in 1 to 3 fractions - Local control rates 100%
- 2-5 year progresión-free survival 20%
T 50 Gy in 10 fractions - 100% 2-year local control
e ADT -Progr. free survival at 2 years 42%
- ADT: median survival free 38 months
in 3 fractions in lymph node
stases and 36 Gy in 3 fractions
ne.
- 32 biochemical response
- 4 PSA stabilization
- 2 PSA progression
- 17 disease progression
- Progression free survival at 30 m:
42,6%.
DT + EBRT (65 Gy) - Biochemical relapse-free survival
at 3 y: 63%
- Overall survival 89%
DT - 66 patients complete biochemical
response
- 12 partial biochemical response
- 1 stable disease
- 15 progression disease
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control with SBRT and an undetectable PSA nadir in nine
(53%) of 17 patients (with 21 lesions), 65% of whom had
hormone-refractory disease [89].
In summary, the major schemes used for treating pros-
tate cancer oligometastases are all based on SBRT, with
an average dose range of one fraction of 20 Gy to three
fractions of 10 Gy. Other schemes used are 5–6 fractions
of 5 or 6 Gy and 10 fractions of 5 Gy, with no discern-
able difference between the two. Concepts such as the
logistics of radiation oncology services and the possible
advantage of hypofractionation doses versus high single
doses should be considered in future studies [90] (Table 1).
Hormone deprivation, as reflected in the 2013 EAU rec-
ommendations, [91], clearly delays clinical progression
and prolongs survival in patients with asymptomatic pros-
tate cancer. Therefore, a phase II clinical trial (currently re-
cruiting) [92] led by Conde et al. at the Hospital Provincial
de Castellón (Spain) and sponsored by the Spanish research
group in radiation oncology (GICOR), the Spanish Society
of Radiation Oncology (SEOR), and the Spanish SBRT
group (SBRT-SG) is seeking to uncover any association
between hormone therapy and SBRT for these oligome-
tastases and whether these treatments can increase local
control, PFS, and chemotherapy-free survival. Another
phase II prospective clinical trial from the University
of Florida is exploring the efficacy and safety of SBRT
in patients with metastatic prostate cancer, either with
or without an active primary tumor, in two subgroups:
castration-resistant and hormone-receptive patients [93].
Other clinical trials include the treatment of prostate oli-
gometastases, but do not focus only in this histology [94]
(Table 2).
In terms of the general role that ablative radiotherapy
has in the management of oligometastases, Tree et al
[95] published a review based on evidence and expert
recommendations. This type of treatment allows a high
degree of treated-metastasis control (around 80%) to
be gained with low toxicity, with 20% of patients being
progression-free two to three years after treatment.
The patients who had longer disease-free intervals
were those with more radiosensitive histologies,
followed by those with pulmonary or colorectal origin
metastases, fewer metastases (1–3), and where high-
dose radiation treatments were administered with a
biologically effective dose higher than 100 Gy. There-
fore these types of treatments are a good option to
consider for patients with isolated metastases (fewer
than 3–5 lesions) and a previous disease-free interval
of more than 6 m. These facts underscore the need for
more randomized trials in order to establish whether
PFS and OS increase when ablative radiotherapy treat-
ments are implemented, as well as to compare them to
surgery.Undoubtedly, the two greatest benefits that have come
from all these types of therapies are the development of
high quality imaging for detecting metastases, and the
knowledge of new molecular markers (such as micro-
RNAs) and their expression patterns, meaning that
tumor biopsies can be used to identify poor-prognosis
oligometastatic patient subgroups who may benefit from
systemic treatments, before or after the discovery of new
metastases. Furthermore, future ablative radiotherapy
treatments may also be administered in combination
with bisphosphonates and denosumab as well as hor-
mone therapy. Moreover, it are expected to the new
anti-androgens (such as abiraterone and enzalutamide)
and target therapy drugs may promote greater control of
systemic disease by acting on micrometastases while
radiation acts on macroscopic disease [96,97] (“Search
strategy and selection criteria”).
Search strategy and selection criteria
Studies were identified in July, 2014, by searches of
PubMed, www.clinicaltrials.gov and Web of Knowledge
(search terms included combinations of oligometastases,
prostate, stereotactic, radiotherapy, metastases, radiosur-
gery, SBRT, and SABR), and by review of cited papers in
selected articles. We identified 435 papers. We assessed
retrospective and prospective studies published in
English. We excluded duplicates or studies reporting a
mixture of hystologies, or non oligometastatic disease.
Studies were eligible if the dose per fraction was 6 Gy
or higher for a total dose of more than 24 Gy, or 5 Gy per
fraction for a total dose of more than 45 Gy. Studies were
excluded if fewer than seven patients were reported or if
median follow-up was less than 12 months. 8 studies in
oligometastatic prostate cancer met the eligibility criteria
for this Review, and 5 focused in SBRT/SRS.
Conclusions
The main conclusions that can be drawn from the
evidence presented here can be summarized in the fol-
lowing points:
1) More clinical and molecular markers which can
classify patients with stage IV cancers are becoming
available.
2) Different approaches must be taken for patients
with polymetastatic, oligometastatic, or
oligo-recurrent disease because these pathologies
are different entities.
3) SBRT and SRS are now alternative treatment
options for oligometastatic patients with various
diseases such as colorectal or lung cancer, and
there is evidence from different studies that
suggests that these treatments may also be a viable
alternative for prostate cancer patients.




Phase Aim Arms Primary objetives Secondary objetives
Radiotherapy for oligometastatic
prostate cancer





2: CR and HN Improvement in median progression-free survival
in patients with metastatic prostate cancer over
historic control rates in hormone receptive and
castration resistant subgroups.
Improvement in overall survival of patients with
metastatic prostate cancer.
University of Florida Treatment failure rates in patients treated with
stereotactic radiation for metastatic prostate cancer.
after type of secondary outcome.
Quality of life in patients treated with stereotactic
radiation for metastatic prostate cancer.
(CTCAE 4.0) adverse events other than a dose-
limiting toxicity which is possibly, probably, or def-
initely related to treatment and which occurs
within 6 months from the start of SBRT to multiple
metastases.
II. To estimate the rates of long-term adverse
events occurring up to 2 years from the end of
SBRT.
III. To explore the most appropriate and clinically
relevant technological parameters to ensure quality
and effectiveness throughout radiation therapy
processes, including imaging, simulation, patient
immobilization, target and critical
structure definition, treatment planning, image
guidance and delivery.
Stereotactic Radiosurgery in
Treating Patients With Metastatic
Breast Cancer, Non-Small Cell
Lung Cancer, or Prostate Cancer
NCT02206334 1 Safety Study 1 To determine the recommended SBRT dose for
each of the metastatic locations being treated
given the individual and overlapping fields when
multiple metastases are treated with SBRT in a
national clinical trials network setting.
I. To estimate rates of > = grade 3
































Table 2 Current ongoing trials for prostate cancer oligometastases in 2014 (www.clinicaltrials.gov) (Continued)
Phase II Study of SBRT as
Treatment for Oligometastases in
Prostate Cancer
NCT02192788 2 Safety and
Efficacy Study
1 Local and symptomatic control of
oligometastases treated by SBRT
Biochemical progression rates
Consorcio Hospitalario Provincial de
Castellón
Collaborators: Progression-free survival,
SBRT-SG Chemotherapy-free survival and overall survival.
GICOR Analyze toxicities and quality of life of patients
before and after treatment
SEOR
CR: Castrate resistant HR: Hormone Receptive NCI: National Cancer Institut RTOG: Radiation Therapy Oncology Group ADT: androgen deprivation therapy.
CTCAE 4.0: Common Terminology Criteria for Adverse Events SBRT-SG: Sterotactic Body Radiation Therapy Spanish Group.
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the role of ablative therapy in the face of increasing
hormone-free and chemotherapy-free survival rates in
oligo-recurrent prostate cancer patients.
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